<DOC>
	<DOC>NCT01951183</DOC>
	<brief_summary>This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety and tolerability of RO6811135 in Type 2 diabetic patients treated with a stable dose of metformin.</brief_summary>
	<brief_title>A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Adults between the age of 18 and 65 Have been diagnosed with diabetes for at least 3 months and treated with a stable dose of metformin for at least 8 weeks Hemoglobin A1c between 7.2 and 10.5% Fasting plasma glucose less than 250 mg/dL Cpeptide greater than 1.5 ng/mL Body mass index (BMI) between 27 and 44 Pregnant or lactating women Type 1 diabetes Had undergone weight loss surgery or weight loss procedure involving the gastrointestinal tract, such as gastric bypass, gastric stapling, or gastric banding Uncontrolled hypertension or other significant cardiovascular disease as determined by investigator Significant kidney or liver disease as determined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>